Lakefront Biotherapeutics NV (AMS:LKFT) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates

Lakefront Biotherapeutics NV (AMS:LKFT) last week reported its latest quarterly results, which makes it a good time for investors to dive in and see if the business is performing in line with expectations. Revenues fell badly short of expectations, with revenue of €6.5m, missing analyst estimates by 74%. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year.

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.ENXTAM:LKFT Earnings and Revenue Growth May 10th 2026

Following the recent earnings report, the consensus from six analysts covering Lakefront Biotherapeutics is for revenues of €270.5m in 2026. This implies a sizeable 74% decline in revenue compared to the last 12 months. Earnings are expected to tip over into lossmaking territory, with the analysts forecasting statutory losses of -€2.87 per share in 2026. Before this earnings announcement, the analysts had been modelling revenues of €172.0m and losses of €2.33 per share in 2026. So there's been quite a change-up of views after the recent consensus updates, with the analysts significantly increasing their revenue forecasts while also expecting losses per share to increase. It looks like the top line growth will not be achieved without incremental costs.

Check out our latest analysis for Lakefront Biotherapeutics

There was no major change to the consensus price target of €30.15, with growing revenues seemingly enough to offset the concern of growing losses. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. Currently, the most bullish analyst values Lakefront Biotherapeutics at €44.80 per share, while the most bearish prices it at €19.00. Note the wide gap in analyst price targets? This implies to us that there is a fairly broad range of possible scenarios for the underlying business.

Of course, another way to look at these forecasts is to place them into context against the industry itself. We would highlight that revenue is expected to reverse, with a forecast 83% annualised decline to the end of 2026. That is a notable change from historical growth of 7.8% over the last five years. Compare this with our data, which suggests that other companies in the same industry are, in aggregate, expected to see their revenue grow 14% per year. It's pretty clear that Lakefront Biotherapeutics' revenues are expected to perform substantially worse than the wider industry.

Story Continues

The Bottom Line

The most important thing to note is the forecast of increased losses next year, suggesting all may not be well at Lakefront Biotherapeutics. Fortunately, they also upgraded their revenue estimates, although our data indicates it is expected to perform worse than the wider industry. The consensus price target held steady at €30.15, with the latest estimates not enough to have an impact on their price targets.

With that said, the long-term trajectory of the company's earnings is a lot more important than next year. At Simply Wall St, we have a full range of analyst estimates for Lakefront Biotherapeutics going out to 2028, and you can see them free on our platform here..

However, before you get too enthused, we've discovered 2 warning signs for Lakefront Biotherapeutics (1 doesn't sit too well with us!) that you should be aware of.

Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

View Comments